Andrew Regan Sells 1,514,100 Shares of Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Stock

Posted by Anthony Miller on Sep 21st, 2024

Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) Director Andrew Regan sold 1,514,100 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $0.26, for a total value of $393,666.00. Following the sale, the director now owns 177,627 shares in the company, valued at $46,183.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Andrew Regan also recently made the following trade(s):

On Monday, July 15th, Andrew Regan sold 1,005,200 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.25, for a total value of $251,300.00.
On Friday, July 12th, Andrew Regan sold 1,389,820 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.25, for a total transaction of $347,455.00.
On Wednesday, July 10th, Andrew Regan sold 150,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.33, for a total transaction of $49,500.00.
On Monday, July 8th, Andrew Regan sold 35,923 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.51, for a total transaction of $18,320.73.
On Wednesday, July 3rd, Andrew Regan sold 1,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.64, for a total transaction of $640.00.

Conduit Pharmaceuticals Price Performance

Shares of NASDAQ CDT opened at $0.14 on Friday. The business has a 50-day moving average of $0.17 and a 200-day moving average of $1.77. Conduit Pharmaceuticals Inc. has a 12 month low of $0.11 and a 12 month high of $22.00.

Conduit Pharmaceuticals (NASDAQ:CDT – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.07) EPS for the quarter.

Analysts Set New Price Targets

Separately, Berenberg Bank raised Conduit Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th.

Get Our Latest Research Report on CDT

Conduit Pharmaceuticals Company Profile

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.